Prostate cancer treatment is built around cutting off androgens, and up to 20% of patients become resistant to it. A 2025 paper points to a different target, the thyroid hormone receptor TRβ, and to a compound called NH-3 that blocks it.
Where current treatment falls short
Prostate cancer is the second most frequent malignancy in men and the sixth leading cause of death worldwide. It involves the growth of abnormal cells in the prostate. Its progression depends on androgen receptor (AR) signalling, which regulates cell proliferation: testosterone and dihydrotestosterone (DHT) activate AR, and that drives cell proliferation and cancer progression.
The first-line treatment is androgen deprivation therapy (ADT), which suppresses testosterone and DHT by surgical castration or anti-androgen drugs. Further treatment uses second-generation AR inhibitors such as enzalutamide.
The problem is drug resistance. Up to 20% of patients develop castration-resistant prostate cancer (CRPC) due to resistance to ADT, and 50% of CRPC patients develop metastatic CRPC in 3 years.
The thyroid hormone link
Recent studies show that thyroid hormones (TH) regulate androgen signalling and the pituitary-gonadal axis. Altered serum levels of THs and thyroid-stimulating hormone (TSH) are linked with an increased risk of prostate cancer, and in vitro, THs promote prostate cancer cell proliferation and tumour progression.
Targeting the receptor is already recognised as a therapeutic strategy. The FDA recently approved resmetirom, a thyroid hormone receptor β (TRβ) agonist, for treating non-alcoholic steatohepatitis.
The basis for the research and drug development involves CRYM, a negative regulator of TH. Previous findings showed reduced expression of CRYM in prostate cancer, and CRYM overexpression has been found to reduce TRβ expression. That makes TRβ a key driver of prostate cancer progression. Since TH promote prostate cancer, CRYM overexpression should be induced to treat it. The metabolic pathway involving CRYM and TRβ has also been shown to crosstalk with AR signalling.
What the 2025 paper found
The paper revealed the role of TRβ in prostate cancer proliferation and tumour development. Human datasets showed increased TRβ protein levels in prostate cancer cells, which points to a tumour-driving role for TRβ.
NH-3, a TRβ-selective antagonist, significantly reduced prostate cancer cell proliferation and suppressed tumour growth. It causes AR degradation and downregulates AR target genes. NH-3 was highly effective in castration-resistant prostate cancer models, and its combined use with AR inhibitors such as enzalutamide was synergistic.
The paper’s summary figure shows NH-3 lowering proliferation and AR in prostate cancer cell lines. In xenograft models (LNCaP and 22Rv1), tumour growth is lowest with NH-3, below both enzalutamide and control. Patient samples show higher TRβ mRNA and protein. The figure labels NH-3 a novel treatment option for prostate cancer and CRPC patients.
Outlook
Current prostate cancer treatment centres on androgen deprivation, including castration and anti-androgen drugs such as enzalutamide. These treatments are ineffective against castration-resistant cancer. Researchers have found an alternative pathway, targeting thyroid hormone receptors, that sidesteps the resistance. NH-3 has proven to be an effective compound using this mechanism, and its combined use with current anti-androgen drugs such as enzalutamide is synergistic.
The method is not available as a treatment for prostate cancer yet. It is still strictly limited to research. With strong evidence of its effectiveness, NH-3 has the potential to become an effective drug for treating prostate cancer. Moving from promising lab results to an approved therapeutic drug, however, still requires rigorous clinical trials and countless rounds of reengineering.
The development of NH-3 for prostate cancer will be an interesting front to watch, and one with high potential.